Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2023-10-23 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document text is extremely short (1067 characters) and contains only digital signature information without any substantive content related to financial performance, management changes, voting results, or other report types. There is no indication of a report, announcement, or detailed information. Given the lack of content and the presence of digital signatures only, this document does not fit into any specific report category and is best classified as a Regulatory Filing (RNS), which serves as a fallback for miscellaneous filings.
2023-10-23 English
Intimation regarding loss of share certificate by the shareholder.
Regulatory Filings Classification · 95% confidence The document text is extremely short (1067 characters) and contains only digital signature information without any substantive content related to financial performance, management changes, voting results, or other report details. There is no mention of any report title, fiscal period, or financial data. The content appears to be a certification or attestation by an individual, likely an officer or authorized signatory. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2023-10-18 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document text is extremely short (1067 characters) and contains only digital signature information without any substantive content related to financial performance, management changes, voting results, or other report details. There is no mention of any report type, fiscal period, or regulatory body. The content appears to be a certification or attestation by an individual rather than a full report or announcement. According to the CERTIFICATION RULE, such documents should be classified as Regulatory Filings (RNS).
2023-10-18 English
Intimation of allotment of 18663 shares under ESOP.
Regulatory Filings Classification · 100% confidence The document text is extremely short (513 characters) and consists solely of a digital signature block with no substantive content related to financial reports, announcements, or filings. There is no mention of any report type, regulatory body, fiscal period, or corporate event. Given the lack of content and the nature of the text, it does not fit any specific filing category and defaults to the fallback category for miscellaneous filings.
2023-10-18 English
ESOP/ESOS/ESPS
Regulatory Filings Classification · 100% confidence The document text is extremely short (513 characters) and contains only a digital signature block with no substantive content related to financial reports, announcements, or filings. There is no mention of any report type, financial data, regulatory body, or corporate event. Given the lack of content and the nature of the text, it does not fit any specific filing category and defaults to the fallback category for miscellaneous filings.
2023-10-18 English
The Company has entered into a Business Transfer Agreement with Lupin Manufacturing Solutions Limited, wholly owned subsidiary of the Company.
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to stock exchanges disclosing a business transfer agreement (BTA) entered into by Lupin Limited with its wholly owned subsidiary. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is an announcement of a corporate transaction (carve out of manufacturing sites and R&D operations) rather than a full report or detailed financial data. The document length is short (2092 characters) and it serves as a regulatory disclosure of a corporate event. This fits best under Capital/Financing Update (CAP) as it relates to a significant corporate restructuring transaction involving business transfer. It is not an annual or interim report, audit, earnings release, or other categories. Therefore, the classification is CAP with high confidence.
2023-10-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.